L2 DIAGNOSTICS LLC
New Haven, CT · Medtech · Private
Capture ELISA assay detecting Babesia microti parasitic protein (BmGPI12/BmSAI) in blood samples
l2dx.com →- Grants
- $26M
- 61 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $4.4M
- 6 awards · Defense, Health and Human S
- #133 of 4531 in medtech
- Patents
- 5
- 1 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20112013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Defense · SBIR Phase 1 Army 11.2 Erms# 11255022, Proposal# A112-106-0883 | $1,146,334 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Inhibition of MIF in Type 1 Diabetes | $297,302 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Inhibition of MIF in Type 1 Diabetes | $297,302 | |
| Federal grant | Department of Health and Human Services · Phase II · A serologic assay to measure successful Lyme borreliosis antibiotic therapy | $879,662 | |
| Federal grant | Department of Health and Human Services · Phase I · A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions | $299,998 | |
| Federal grant | Department of Health and Human Services · Phase I · RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens | $825,690 | |
| Federal grant | Department of Health and Human Services · Phase II · Measurement of Beta Cell Death in Diabetes | $686,590 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf | $271,237 | |
| Federal grant | Department of Health and Human Services · Phase I · Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma | $298,959 | |
| Federal grant | Department of Health and Human Services · Phase II · A serologic assay to measure successful Lyme borreliosis antibiotic therapy | $879,662 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection | $300,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy | $694,516 | |
| Federal grant | Department of Health and Human Services · Phase I · A Rapid, Low-Cost Point of Care Diagnostic for detection of Zika virus RNA | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A Rapid Low Cost Point of Care Diagnostic for detection of Zika virus RNA | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy | $6,092 | |
| Federal grant | Department of Health and Human Services · Phase I · Validation of a Diagnostic Test for Borrelia miyamotoi | $299,905 | |
| Federal grant | Department of Health and Human Services · Phase II · Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy | $780,982 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy | $299,754 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy | $299,754 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf SBIR Phase II: Topic 338 - Predictive Biomarkers Of Adverse Reactions To Prostrate Cancer Radiotherapy | $1,996,011 | |
| Federal grant | Department of Health and Human Services · Phase I · An antigen-detection assay to diagnose Babesia microti infection | $299,975 | |
| Federal grant | Department of Health and Human Services · Phase I · An antigen-detection assay to diagnose Babesia microti infection | $299,975 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Inhibition of MIF to Improve Glucocorticoid Response | $299,407 | |
| Federal contract | Department of Defense · Lyme Test Plates | $54,980 | |
| Federal grant | Department of Health and Human Services · Phase I · Validation of a Diagnostic Test for Borrelia miyamotoi | $274,312 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a Point of Care Diagnostic Screening test for Kawasaki disease | $224,963 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus | $225,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Inhibition of MIF to Improve Glucocorticoid Response | $154,035 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 | $299,888 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunization with mosquito AgTRIO protein to prevent malaria | $298,944 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of A Narrow Spectrum Anti-Tubercular Agent | $299,661 | |
| Federal grant | Department of Health and Human Services · Phase I · Targets of Acquired Tick-Resistance As Anti-Tick Vaccines | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Targets of Acquired Tick-Resistance As Anti-Tick Vaccines | $596,625 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity | $298,911 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity | $298,911 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 | $294,338 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunization with mosquito AgTRIO protein to prevent malaria | $293,394 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of A Narrow Spectrum Anti-Tubercular Agent | $285,676 | |
| Federal grant | Department of Health and Human Services · Phase I · Vaccination against Zika virus infection using mosquito NeSt1 protein | $299,200 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · An antigen-detection assay to diagnose Babesia microti infection | $2,076,246 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · An antigen-detection assay to diagnose Babesia microti infection | $692,082 | |
| Federal grant | Department of Health and Human Services · Phase I · Targets of Acquired Tick-Resistance As Anti-Tick Vaccines | $296,626 | |
| Federal grant | Department of Health and Human Services · Phase II · An antigen-detection assay to diagnose Babesia microti infection | $692,082 | |
| Federal grant | Department of Health and Human Services · Phase I · Vaccination against Zika virus infection using mosquito NeSt1 protein | $293,886 | |
| Federal grant | Department of Health and Human Services · Phase I · A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1 | $299,514 | |
| Federal grant | Department of Health and Human Services · Phase II · An antigen-detection assay to diagnose Babesia microti infection | $692,082 | |
| Federal grant | Department of Health and Human Services · Phase I · A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1 | $299,514 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 | $988,360 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 | $979,482 | |
| Federal grant | Department of Health and Human Services · Phase I · A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens | $298,362 | |
| Federal grant | Department of Health and Human Services · Phase I · Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches | $299,878 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor | $299,933 | |
| Federal grant | Department of Health and Human Services · Phase I · The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya | $299,969 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1 | $980,219 | |
| Federal contract | Department of Health and Human Services · Novel Diagnostic Biomarkers Discovery And Validation For Malaria SBIR Phase I | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens | $299,250 | |
| Federal grant | Department of Health and Human Services · Phase I · Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches | $299,862 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor | $299,933 | |
| Federal grant | Department of Health and Human Services · Phase I · The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya | $299,969 | |
| Federal contract | Department of Health and Human Services · Therapeutic Vaccine Platform To Boost Immune Responses In Tuberculosis | $599,471 | |
| Federal grant | Department of Health and Human Services · Phase I · PfAg, a multivalent peptide vaccine against malaria | $299,954 | |
| Federal grant | Department of Health and Human Services · Phase I · A Point of Care Test for Babesia microti | $293,142 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A vaccine targeting mosquito metabolic pathways to eradicate malaria | $299,644 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A viral vector-based vaccine to induce humoral and cellular immune protection against Powassan virus in a tick transmission model | $281,786 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 130 | ACTUATED MEDICAL, INC. | $4.6M | $150K |
| 131 | ROBIN MEDICAL INC | $4.5M | — |
| 132 | ADAPTIVE BIOTECHNOLOGIES CORPORATION | $4.4M | $507M |
| 133 | L2 DIAGNOSTICS LLC | $4.4M | — |
| 134 | NUSHORES BIOSCIENCES LLC | $4.3M | $350K |
| 135 | TRACE BIOSCIENCES INC | $4.2M | — |
| 136 | ShockWave Medical, Inc. | $4.2M | $110M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Assays For Diagnosing Type 1 Diabetesgranted
- Erbb Peptide Pharmaceutical And Vaccine Compositions And Therapeutics Uses Thereof For Cancerapplication
- Erbb Peptide Pharmaceutical And Vaccine Compositions And Therapeutic Uses Thereof For Cancerapplication
- Assays And Reagents For Diagnosing Type 1 Diabetesapplication
- Compositions And Methods Comprising West Nile Virus Polypeptidesapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.